NCT05724472View on ClinicalTrials.gov

Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 19, 2023

Primary Completion Date

January 9, 2024

Study Completion Date

January 9, 2024

Conditions
Ebola Sudan Virus Disease
Interventions
DRUG

rVSV∆G-SEBOV-GP Vaccine or Placebo

rVSV∆G-SEBOV-GP Vaccine or Placebo

Trial Locations (2)

78229

Clinical Trials of Texas, San Antonio

78705

Benchmark Research, Austin

All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

International AIDS Vaccine Initiative

NETWORK